We read with great interest the work by Deng Q. et al. who provide valuable, front-line data regarding myocardial injury in Coronavirus Disease -- 19 (COVID-19) hospitalized patients \[[@bb0005]\]. Myocardial involvement has been recognized as a component of COVID-19 in a noteworthy proportion of patients (ranging up to 40% of the cases) and has been related to mortality. Indeed, cardio-protection in COVID-19 - regarding both myocardial necrosis and inflammation - is a target of ongoing research \[[@bb0010]\]. Do myocardial necrosis\' biomarkers act as an unpleasant bystander who provides clinicians an early sign of adverse outcomes or are they indicative of direct myocardial involvement? Deng. et al. \[[@bb0005]\] suggest, that myocardium is mainly hit in a secondary fashion (i.e. oxygen demand/supply in myocardial cell level). Of course, lack of biopsy and/or MRI data in their cohort is noted as limitation for this argument; however, authors supported this viewpoint on already published autopsy reports \[[@bb0005]\]. Still, our knowledge on the field changes rapidly. To date, a series of cases proving diverse mechanisms of direct myocardial injury has been published: histological proved virus-positive SARS-CoV-2 myocarditis \[[@bb0015]\], virus-negative lymphocytic myocarditis associated with SARS-CoV-2 respiratory infection (clinically presented as reverse-takotsubo) \[[@bb0020]\] and true takotsubo syndrome \[[@bb0025]\]. These reports do not contradict (but, indeed, are in line) with the findings of Deng et al. \[[@bb0005]\], but COVID-19 being a new entity for clinicians and researchers, they do remind us of the Socratic paradox: "The only thing I know is that I know nothing".
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